What is the appropriate workup for CD57-positive natural killer (NK) cells?

Workup for CD57+ NK Cells

CD57+ NK cells are assessed through flow cytometry immunophenotyping as part of a comprehensive lymphocyte subset analysis, primarily used in the context of lymphoproliferative disorders, immune monitoring, or specific disease states where NK cell maturation and function are clinically relevant.

Clinical Context and Indications

CD57+ NK cells represent a mature, terminally differentiated subset within the CD56dim NK cell population 1. The workup for CD57+ NK cells is typically indicated in several clinical scenarios:

• Lymphoproliferative disorders: When evaluating mature lymphoid neoplasms, particularly NK/T-cell lymphomas 2, 3
• Transplant monitoring: Assessment of antibody-mediated rejection in solid organ transplantation 4
• Viral infections: Monitoring immune response during CMV infection or reactivation 5
• Autoimmune conditions: Evaluation of immune dysregulation in conditions like primary sclerosing cholangitis or NAFLD 6, 7

Essential Workup Components

Blood Specimen Collection and Processing

• Specimen type: EDTA-anticoagulated whole blood 8, 9
• Timing: Process within 30 hours optimally, but no later than 48 hours after collection 9
• Temperature: Maintain at room temperature; reject if specimen is hot, cold, hemolyzed, or frozen 9
• Volume: Sufficient to ensure proper lymphocyte-to-antibody ratio per manufacturer specifications 8

Hematologic Testing

• Complete blood count with differential: Automated WBC count and differential counting 10,000-30,000 cells 9
• Absolute lymphocyte count: Required for calculating absolute NK cell subset values 8, 9

Immunophenotyping Panel

Core NK cell identification markers 8, 9, 10:

• CD3 (negative on NK cells)
• CD56 (defines NK cells; CD56dim is the primary mature subset)
• CD16 (typically positive on mature NK cells)
• CD57 (identifies terminally differentiated/mature NK cells)

Extended panel for comprehensive NK cell assessment 9, 10:

• CD45 (for lymphocyte gating and identification)
• CD19 (B-cell marker, for accounting all lymphocytes)
• CD16 and/or CD56 (NK cell markers)
• NKG2A, NKG2C (activating/inhibitory receptors)
• KIR receptors (CD158a, CD158b, CD158e1) when indicated 11
• CD94 (paired with NKG2 receptors)

Flow Cytometry Methodology

Technical requirements 8, 9, 8:

• Use direct two-color, three-color, or four-color immunofluorescence whole-blood lysis method
• Employ "stain, then lyse" procedure
• Fix samples with 1-2% buffered paraformaldehyde after staining and lysing
• Store stained samples in dark at 4-10°C until analysis (within 24 hours) 10

Quality control parameters 8, 9:

• Lymphocyte recovery: ≥90% minimum, ≥95% optimal
• Lymphocyte purity within gate: ≥85% minimum, ≥90% optimal
• CD3 values across tubes should be within 3% of each other
• Sum of T-cells (CD3+), B-cells (CD19+), and NK-cells should equal lymphocyte purity ±5-10%

Data Analysis and Reporting

NK Cell Subset Identification

CD57+ NK cells are specifically identified as 1, 5:

• CD3-negative
• CD56dim (low CD56 expression)
• CD16-positive
• CD57-positive

This subset represents highly mature, terminally differentiated NK cells with enhanced cytotoxic capacity but decreased proliferative potential 1.

Reporting Requirements

Report the following parameters 8, 9:

• Percentage of CD57+ cells within total NK cells
• Percentage of CD57+ cells within CD56dim NK subset
• Absolute count of CD57+ NK cells (calculated by multiplying percentage by absolute lymphocyte count)
• Expression levels of additional markers (NKG2C, NKG2A, KIR) when assessed 11, 5

Disease-Specific Considerations

For Suspected NK/T-Cell Lymphomas

Additional essential workup 2:

• EBV viral load by quantitative PCR
• EBER in situ hybridization on tissue
• Bone marrow biopsy with aspirate
• Comprehensive metabolic panel, LDH, uric acid
• CT imaging of involved sites
• Typical NK-cell immunophenotype: CD20-, CD2+, cytoplasmic CD3ε+ (surface CD3-), CD56+, cytotoxic granule proteins positive 2, 3

For Transplant Recipients

• Serial monitoring of CD57+CD56+ NK cell infiltrates correlates with antibody-mediated rejection 4
• Increased density of NK cells (particularly CD56+CD57+) in biopsy specimens indicates higher risk of graft failure 4

For Viral Infection Monitoring

• CD57+NKG2Chi NK cells expand preferentially during acute CMV infection 5
• Serial measurements can track immune response and viral reactivation 5

Common Pitfalls and Caveats

Technical considerations:

• CD57 expression increases with age; newborns and infants have very few CD57+ NK cells 1
• Avoid using abbreviated panels that lack internal controls for tube-to-tube variability 9
• Ensure proper spectral compensation to prevent fluorochrome spillover 9, 12
• Pre-wash specimens with PBS if spectral compensation appears inappropriate 8, 12

Interpretation caveats:

• CD57+ NK cells have decreased proliferative capacity but enhanced cytotoxicity through CD16 stimulation 1
• These cells are less responsive to IL-12 and IL-18 cytokine stimulation 1
• CD57 expression may indicate "memory" NK cells expanded in response to prior infections 5
• Decreased CD57 expression can paradoxically indicate enhanced cytotoxicity in certain autoimmune conditions 6